Amgen Inc. (NASDAQ: AMGN), a leading biopharmaceutical company based in the U.S., has decided to halt the development of AMG 794, a half-life extended BiTE (bispecific T-cell engager) immune therapy that targets the oncofetal antigen Claudin 6 (CLDN6). This decision was disclosed on the clinicaltrials.gov website under the identifier NCT05317078, which corresponds to a Phase I first-in-human study. The study was initially designed to treat patients with CLDN6-positive advanced or metastatic non-small cell lung cancer, epithelial ovarian cancer, and other solid tumor types.
Initiated in February 2023, the study had enrolled only three patients prior to its termination, as reported on clinicaltrials.gov. The termination has been attributed to a business decision, with no changes to the safety profile of AMG 794 noted.- Flcube.com
